Premium
Epstein‐Barr virus‐associated smooth muscle tumor in a kidney transplant recipient: A case‐report and review of the literature
Author(s) -
Tardieu Laurène,
Meatchi Tchao,
Meyer Lara,
Grataloup Christine,
BernardTessier Alice,
Karras Alexandre,
Thervet Eric,
Lazareth Hélène
Publication year - 2021
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13456
Subject(s) - medicine , immunosuppression , seroconversion , kidney transplantation , transplantation , epstein–barr virus , lymphoproliferative disorders , hemodialysis , kidney , virus , lymphoma , gastroenterology , immunology
Epstein‐Barr virus (EBV) is a herpesvirus linked to pre‐malignant lymphoproliferative diseases and up to nine distinct human tumors. The most frequent EBV‐associated malignancies are lymphomas and nasopharyngeal carcinoma. By promoting smooth muscle proliferation, EBV can induce EBV‐associated smooth muscle tumors (SMT) which remain a very rare oncological entity. This study reports one case report of SMT and aims to offer the largest review of literature on post‐transplantation‐SMT (PT‐SMT) in kidney transplant recipients, with a focus on therapeutic management and evolution of graft function. Methods Case reports and case series of PT‐SMT in kidney transplant recipients were collected from 1996 to 2019. Results A total of 59 PT‐SMT were evaluated. The median time at diagnosis was 74.6 months after kidney transplantation. The most frequent localizations were liver and lung. EBV seroconversion was notified in all six patients with previously negative status. Preferred therapeutic option was surgery (65.9%), associated with a reduction in immunosuppression (77.2%), which includes switch to mTOR inhibitors (29.5%), and discontinuation of MMF (32%). In our review, 13% of patients experienced rejection, 8.7% lost their graft and went back on hemodialysis; 8.8% of patients died of PT‐SMT. Conclusion PT‐SMT is a rare but serious condition in kidney transplant recipients. EBV seroconversion following transplantation appears as a risk factor in developing PT‐SMT in solid‐organ recipients. In the absence of guidelines, therapeutic management for PT‐SMT is challenging and exposes the patient to high risk of graft loss.